Differences in the peritoneal response to pristane in BALB/cAnPt and BALB/cJ mice.

A. Anderson,J. Wax,M. Potter

DOI: https://doi.org/10.1007/978-3-642-70740-7_34

Current topics in microbiology and immunology

Abstract:

What problem does this paper attempt to address?

Stroke and Distal Organ Damage: Exploring Brain-Kidney Crosstalk

Vandana Dulam,Sireesha Katta,Venkata Prasuja Nakka

DOI: https://doi.org/10.1007/s11064-024-04126-8

IF: 4.4

2024-02-21

Neurochemical Research

Abstract:Stroke and kidney dysfunction represent significant public health challenges, yet the precise mechanisms connecting these conditions and their severe consequences remain unclear. Individuals experiencing chronic kidney disease (CKD) and acute kidney injury (AKI) are at heightened susceptibility to experiencing repeated strokes. Similarly, a reduced glomerular filtration rate is associated with an elevated risk of suffering a stroke. Prior strokes independently contribute to mortality, end-stage kidney disease, and cardiovascular complications, underscoring the pathological connection between the brain and the kidneys. In cases of AKI, various mechanisms, such as cytokine signaling, leukocyte infiltration, and oxidative stress, establish communication between the brain and the kidneys. The bidirectional relationship between stroke and kidney pathologies involves key factors such as uremic toxins, proteinuria, inflammatory responses, decreased glomerular filtration, impairment of the blood-brain barrier (BBB), oxidative stress, and metabolites produced by the gut microbiota. This review examines potential mechanisms of brain-kidney crosstalk underlying stroke and kidney diseases. It holds significance for comprehending multi-organ dysfunction associated with stroke and for formulating therapeutic strategies to address stroke-induced kidney dysfunction and the bidirectional pathological connection between the kidney and stroke.

biochemistry & molecular biology,neurosciences
Kidney–brain crosstalk in the acute and chronic setting

Renhua Lu,Matthew C. Kiernan,Anne Murray,Mitchell H. Rosner,Claudio Ronco

DOI: https://doi.org/10.1038/nrneph.2015.131

IF: 42.439

2015-08-18

Nature Reviews Nephrology

Abstract:Key PointsThe majority of patients with chronic kidney disease (CKD) incur neurological complications that might improve following renal transplantationProteinuria, decreased glomerular filtration rate (GFR), and increased cystatin C are risk factors for cerebrovascular disease, which is in turn a risk factor for ongoing kidney dysfunctionStroke is a major complication of CKD in elderly patients undergoing dialysis; conventional ischaemic risk factors, as well as dialysis itself, can contribute to the development of strokePatients undergoing dialysis often develop delirium after dialysis sessions, as well as chronic dementia, with prominent deficits in executive function and memory that are independent of ageSystemic inflammation, oxidative stress, and dysregulation of sodium, potassium, and water channels in acute kidney injury can lead to brain injury, dysfunction, and oedema

urology & nephrology
Cerebrovascular Disease, Cardiovascular Disease, and Chronic Kidney Disease: Interplays and Influences

J David Spence,Bradley L Urquhart

DOI: https://doi.org/10.1007/s11910-022-01230-6

Abstract:Purpose of review: We reviewed reasons for the high cardiovascular risk (CVD) of patients with chronic kidney disease (CKD), and explored alternatives to treatment of traditional risk factors to reduce CVD in CKD. Recent findings: Besides traditional risk factors, patients with CKD are exposed to uremic toxins of two kinds: systemically derived toxins include asymmetric dimethylarginine (ADMA), total homocysteine (tHcy), thiocyanate, tumor necrosis factor alpha, and interleukin 6. Gut-derived uremic toxins (GDUT), products of the intestinal microbiome, include hippuric acid, indoxyl sulfate, p-cresyl sulfate, p-cresyl glucuronide, phenylacetylglutamine, and trimethylamine N-oxide (TMAO). Cyanocobalamin is toxic in patients with CKD. Approaches to reducing plasma levels of these uremic toxins would include diet to reduce GDUT, kidney transplantation, more intensive dialysis, and vitamin therapy to lower tHcy with methylcobalamin rather than cyanocobalamin. The high CVD risk in CKD requires consideration of therapies beyond treatment of traditional risk factors.
Mechanisms of Stroke in Patients with Chronic Kidney Disease

Shivani Ghoshal,Barry I Freedman

DOI: https://doi.org/10.1159/000502446

Abstract:Background: Given the increasing worldwide prevalence of chronic kidney disease (CKD), it is critical to decrease the associated risk of debilitating vascular complications, including stroke, congestive heart failure, myocardial infarction, and peripheral vascular disease. Treatment options for reducing the risk of all subtypes of stroke in patients with CKD remain limited. For patients with end-stage kidney disease (ESKD), novel applications of noninvasive imaging may help personalize the type of dialysis and dialysis prescription for patients at high-risk. Summary: This manuscript reviews the heightened risk of stroke in patients with nephropathy, including ischemic and hemorrhagic subtypes. Mechanisms associated with increased risk include alterations in cardiac output, platelet function, regional cerebral perfusion, accelerated systemic atherosclerosis, altered blood brain barrier, and disordered neurovascular coupling. There is great potential for noninvasive monitoring of the cerebral vasculature using transcranial Doppler (TCD) to reduce stroke risk, particularly in patients with ESKD. Key Messages: Compared to the general population, patients with CKD are at heightened risk for all subtypes of stroke. This is due to a multitude of mechanisms linking nephropathy with altered cerebral perfusion, cerebral neurovascular coupling, and blood vessel integrity. Intracranial imaging is not currently standard of care practice in patients with CKD or ESKD. TCD may provide clinicians real-time and noninvasive measurement of brain perfusion. This could be useful for assessing risk of stroke in patients' initiating dialysis, individualizing dialysis prescriptions, and potentially reducing rates of cerebrovascular disease and stroke in high-risk patients.
Stroke‐Induced Renal Dysfunction: Underlying Mechanisms and Challenges of the Brain–Kidney Axis

Xi Chen,Dong‐Xiao Yang,Heng Zhao,Hong‐Fei Zhang,Pu Hong

DOI: https://doi.org/10.1111/cns.70114

2024-11-16

CNS Neuroscience & Therapeutics

Abstract:After a stroke, multiple pathways in the neurohumoral system are activated. At the same time, the blood–brain barrier is compromised, and pro‐inflammatory substances are released from the brain into the bloodstream, consequently activating the peripheral inflammatory immune response. As an acute injury, stroke triggers renal hemodynamic disturbances and an acute ischemic state in the kidney, thereby promoting the development of AKI or CKD. Stroke, a major neurological disorder and a leading cause of disability and death, often inflicts damage upon other organs, particularly the kidneys. While chronic kidney disease (CKD) has long been established as a significant risk factor for cerebrovascular disease, stroke can induce renal dysfunction, manifesting as acute kidney injury (AKI) or CKD. Mounting clinical and basic research evidence supports the existence of a bidirectional brain‐kidney crosstalk following stroke, implicating specific mechanisms and pathways in stroke‐related renal dysfunction. This review analyzes pertinent experimental studies, elucidating the underlying mechanisms of this cerebro‐renal interaction following stroke. Additionally, we summarize the current landscape of clinical research investigating brain‐kidney interplay and discuss potential challenges in the future. By enhancing our understanding of the scientific underpinnings of brain‐kidney crosstalk, this review paves the way for improved treatment strategies and outcomes for stroke patients. Recognizing the intricate interplay between the brain and kidneys after stroke holds profound clinical implications.

pharmacology & pharmacy,neurosciences
Navigating the Crossroads: Understanding the Link Between Chronic Kidney Disease and Cardiovascular Health

Danish Saeed,Taufiqa Reza,Muhammad Waqas Shahzad,Alishba Karim Mandokhail,Danyal Bakht,Farwa Haider Qizilbash,Elizabeth O Silloca-Cabana,Afif Ramadhan,Syed Faqeer Hussain Bokhari

DOI: https://doi.org/10.7759/cureus.51362

2023-12-30

Cureus

Abstract:Chronic Kidney Disease (CKD) has emerged as a global healthcare challenge affecting a significant portion of the world's population. This comprehensive narrative review delves into the intricate relationship between CKD and cardiovascular disease (CVD). CKD is characterized by kidney damage persisting for at least three months, often with or without a decline in glomerular filtration rate (GFR). It is closely linked with CVD, as individuals with CKD face a high risk of cardiovascular events, making cardiovascular-associated mortality a significant concern in advanced CKD stages. The review emphasizes the importance of precise risk assessment using biomarkers, advanced imaging, and tailored medication strategies to mitigate cardiovascular risks in CKD patients. Lifestyle modifications, early intervention, and patient-centered care are crucial in managing both conditions. Challenges in awareness and recognition of CKD and the need for comprehensive interdisciplinary care are highlighted. Recent advances in research offer promising therapies, such as SGLT2 inhibitors, MRAs, GLP-1R agonists, and selective endothelin receptor antagonists. Stem cell-based therapies, gene editing, and regenerative approaches are under investigation. Patient-physician "risk discussions" and tailored risk assessments are essential for improving patient outcomes. In conclusion, the review underscores the complexity of the interconnected CKD and cardiovascular health domains. Ongoing research, innovative therapies, and personalized healthcare will be instrumental in addressing the challenges, reducing the disease burden, and enhancing well-being for individuals facing CKD and cardiovascular issues. Recognizing the intricate connections between these conditions is imperative for healthcare providers, policymakers, and researchers as they seek to improve the quality of care and outcomes for affected individuals.
Epidemiology and Mechanisms of Uremia-Related Cardiovascular Disease.

R. Thadhani,S. Karumanchi,M. Tonelli

DOI: https://doi.org/10.1161/CIRCULATIONAHA.115.018713

IF: 37.8

2016-02-02

Circulation

Abstract:Patients with chronic kidney disease and end-stage renal disease are at 5- to 10-fold higher risk for developing cardiovascular disease (CVD) than age-matched controls. Clinically, CVD in this population manifests as coronary artery disease, arrhythmias, stroke, or congestive heart failure. Beyond the traditional risk factors (eg, diabetes mellitus and hypertension), uremia-specific factors that arise from accumulating toxins also contribute to the pathogenesis of CVD. In this review, we summarize the literature on the epidemiology of both traditional and uremia-related CVD and focus on postulated mechanisms of the latter. In the context of current and emerging diagnostics and therapies for CVD, we highlight what we interpret as major gaps in the medical management of this growing population that need to be addressed with targeted epidemiological and translational research. Finally, we describe the global challenges associated with the recognition and management of uremia-related CVD in developed and developing nations.

Medicine,Environmental Science
A general four-parameter non-FSAL embedded Runge-Kutta algorithm of orders 6 and 4 in seven stages

Moawwad E. A. El-Mikkawy,M. Eisa

DOI: https://doi.org/10.1016/S0096-3003(02)00358-2

IF: 4.397

2003-11-10

Applied Mathematics and Computation

Abstract:
The impact of chronic kidney disease on prognosis in acute stroke: unraveling the pathophysiology and clinical complexity for optimal management

Kruthajn Rajesh,Kevin J. Spring,Ivica Smokovski,Vedant Upmanyue,Man Mohan Mehndiratta,Giovanni F. M. Strippoli,Roy G. Beran,Sonu M. M. Bhaskar

DOI: https://doi.org/10.1007/s10157-024-02556-w

IF: 2.6212

2024-12-05

Clinical and Experimental Nephrology

Abstract:Chronic kidney disease (CKD) significantly increases stroke risk and severity, posing challenges in both acute management and long-term outcomes. CKD contributes to cerebrovascular pathology through systemic inflammation, oxidative stress, endothelial dysfunction, vascular calcification, impaired cerebral autoregulation, and a prothrombotic state, all of which exacerbate stroke risk and outcomes.

urology & nephrology
Stroke in Dialysis and Chronic Kidney Disease

Albert Power

DOI: https://doi.org/10.1159/000356086

2013-01-01

Blood Purification

Abstract:BACKGROUND: Renal impairment is a potent risk factor for stroke that is a leading cause of morbidity and mortality worldwide. Dialysis patients experience a 10-fold higher incidence, with case fatality rates reaching 90%. It is important to understand the factors predisposing to stroke in patients with chronic kidney disease (CKD) coupled with an appreciation of preventative strategies.SUMMARY: The heightened risk of stroke in CKD represents the interplay of the vascular comorbidities that cluster with renal impairment as well as pathology inherent in uremia, such as accelerated vascular calcification and the malnutrition-inflammation-atherosclerosis syndrome. These factors are most marked in hemodialysis where stroke rates peak at 10-35/1,000 patient years and where hemorrhagic stroke accounts for 20-30% of all events. Older age, hypertension, diabetes and established cerebrovascular disease are all risk factors for stroke with dialysis initiation constituting the highest risk period. Patients with CKD stages 3-5D have worse survival as well as diminished functional outcomes following stroke. Thrombolytic therapy for acute stroke appears safe in all stages of CKD although the therapeutic effect may be attenuated. Control of hypertension and the use of antiplatelet agents form the mainstay of stroke prevention. The benefit of antiplatelet therapies and oral anticoagulants must be balanced against the real risks of bleeding that are most evident in dialysis cohorts.KEY MESSAGES: Understanding the risks and benefits of established stroke treatments is vital in patients with CKD, especially in those on dialysis therapies who are at highest risk of adverse outcomes.

hematology,urology & nephrology
Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches

Philip Düsing,Andreas Zietzer,Philip Roger Goody,Mohammed Rabiul Hosen,Christian Kurts,Georg Nickenig,Felix Jansen

DOI: https://doi.org/10.1007/s00109-021-02037-7

2021-01-22

Journal of Molecular Medicine

Abstract:Abstract Cardiovascular disease (CVD) is a major cause of death in patients with chronic kidney disease (CKD). Both conditions are rising in incidence as well as prevalence, creating poor outcomes for patients and high healthcare costs. Recent data suggests CKD to be an independent risk factor for CVD. Accumulation of uremic toxins, chronic inflammation, and oxidative stress have been identified to act as CKD-specific alterations that increase cardiovascular risk. The association between CKD and cardiovascular mortality is markedly influenced through vascular alterations, in particular atherosclerosis and vascular calcification (VC). While numerous risk factors promote atherosclerosis by inducing endothelial dysfunction and its progress to vascular structural damage, CKD affects the medial layer of blood vessels primarily through VC. Ongoing research has identified VC to be a multifactorial, cell-mediated process in which numerous abnormalities like mineral dysregulation and especially hyperphosphatemia induce a phenotype switch of vascular smooth muscle cells to osteoblast-like cells. A combination of pro-calcifying stimuli and an impairment of inhibiting mechanisms like fetuin A and vitamin K-dependent proteins like matrix Gla protein and Gla-rich protein leads to mineralization of the extracellular matrix. In view of recent studies, intercellular communication pathways via extracellular vesicles and microRNAs represent key mechanisms in VC and thereby a promising field to a deeper understanding of the involved pathomechanisms. In this review, we provide an overview about pathophysiological mechanisms connecting CKD and CVD. Special emphasis is laid on vascular alterations and more recently discovered molecular pathways which present possible new therapeutic targets.
[Staphylococcal infection in a surgical clinic (review of foreign literature)].

K. E. Rudiak,I. N. Ulanovskii,I. Turovets

Abstract:
Novel Perspectives in Chronic Kidney Disease-Specific Cardiovascular Disease

Cuicui Xu,George Tsihlis,Katrina Chau,Katie Trinh,Natasha M. Rogers,Sohel M. Julovi

DOI: https://doi.org/10.3390/ijms25052658

IF: 5.6

2024-02-25

International Journal of Molecular Sciences

Abstract:Chronic kidney disease (CKD) affects > 10% of the global adult population and significantly increases the risk of cardiovascular disease (CVD), which remains the leading cause of death in this population. The development and progression of CVD—compared to the general population—is premature and accelerated, manifesting as coronary artery disease, heart failure, arrhythmias, and sudden cardiac death. CKD and CV disease combine to cause multimorbid cardiorenal syndrome (CRS) due to contributions from shared risk factors, including systolic hypertension, diabetes mellitus, obesity, and dyslipidemia. Additional neurohormonal activation, innate immunity, and inflammation contribute to progressive cardiac and renal deterioration, reflecting the strong bidirectional interaction between these organ systems. A shared molecular pathophysiology—including inflammation, oxidative stress, senescence, and hemodynamic fluctuations characterise all types of CRS. This review highlights the evolving paradigm and recent advances in our understanding of the molecular biology of CRS, outlining the potential for disease-specific therapies and biomarker disease detection.

biochemistry & molecular biology,chemistry, multidisciplinary
Neuropsychiatric Disorders in Chronic Kidney Disease

Ana Cristina Simões e Silva,Aline Silva Miranda,Natalia Pessoa Rocha,Antônio Lúcio Teixeira

DOI: https://doi.org/10.3389/fphar.2019.00932

IF: 5.6

2019-08-16

Frontiers in Pharmacology

Abstract:Neuropsychiatric conditions including depression, anxiety disorders, and cognitive impairment are prevalent in patients with chronic kidney disease (CKD). These conditions often make worse the quality of life and also lead to longer hospitalizations and higher mortality. Over the past decades, some hypotheses have tried to explain the connection between CKD and neuropsychiatric disorders. The most common hypothesis is based on the occurrence of cerebrovascular disease and accumulated uremic toxins in adult patients with CKD. However, the lack of a direct association between known vascular risk factors (e.g., diabetes and hypertension) with CKD-related cognitive deficits suggests that other mechanisms may also play a role in the pathophysiology shared by renal and neuropsychiatric diseases. This hypothesis is corroborated by the occurrence of neuropsychiatric comorbidities in pediatric patients with CKD preceding vascular damage, and the inconsistent findings on neuroprotective effects of antihypertensives. The aim of this narrative review was to summarize clinical evidence and potential mechanisms that links CKD and brain disorders, specifically in regard to cognitive impairment, anxiety, and depression.

pharmacology & pharmacy
Performance of a hybrid-loop bioreactor system in biological treatment of 2,4,6-tri-chlorophenol containing synthetic wastewater: effects of hydraulic residence time.

Serkan Eker,F. Kargı

DOI: https://doi.org/10.1016/J.JHAZMAT.2006.09.084

IF: 13.6

2007-06-01

Journal of Hazardous Materials

Abstract:
The impact of chronic kidney disease on cognitive function

Marion Pépin,Hélène Levassort,Ziad A Massy

DOI: https://doi.org/10.1097/MNH.0000000000001017

2024-11-01

Abstract:Purpose of review: The risk of cognitive impairment is higher in people with CKD than in the general population. The complex relationship between CKD and cognitive dysfunction has not been extensively characterized. Here, we review epidemiological associations, specific patterns of CKD-related cognitive impairment, the underlying mechanisms, and recently published data on relevant biomarkers. Recent findings: Despite some discrepancies, recent published studies have confirmed that CKD is associated with cognitive function (e.g. incident cognitive events). Although patients with CKD often exhibit impairments in executive functions and attention, it is noteworthy that other cognitive functions (e.g. memory) can be preserved. The key mechanisms described recently include vascular damage, genetic factors, the accumulation of uremic toxins, disruption of the blood-brain barrier, glymphatic system dysfunction, and changes in the gut-brain axis. Kidney function is increasingly seen as a game changer in the interpretation of biomarkers of cognitive impairment and, especially, hallmarks of Alzheimer disease. Summary: The data reviewed here highlight the need for interdisciplinary collaboration between nephrologists and neurologists in the care of patients with CKD at risk of cognitive impairment. In order to further improving diagnosis and therapy, future research must elucidate the mechanisms underlying the CKD-cognitive impairment association and confirm the value of biomarkers.
Technische und organisatorische Aspekte von Softwaretests (Technical and organizational aspects of testing software)

Tim A. Majchrzak

Abstract:
Kidney-brain axis in the pathogenesis of cognitive impairment

Qianqian Yan,Mengyuan Liu,Yiling Xie,Yimi Lin,Ping Fu,Yaoyu Pu,Bo Wang

DOI: https://doi.org/10.1016/j.nbd.2024.106626

2024-10-01

Abstract:The kidney-brain axis is a bidirectional communication network connecting the kidneys and the brain, potentially affected by inflammation, uremic toxin, vascular injury, neuronal degeneration, and so on, leading to a range of diseases. Numerous studies emphasize the disruptions of the kidney-brain axis may contribute to the high morbidity of neurological disorders, such as cognitive impairment (CI) in the natural course of chronic kidney disease (CKD). Although the pathophysiology of the kidney-brain axis has not been fully elucidated, epidemiological data indicate that patients at all stages of CKD have a higher risk of developing CI compared with the general population. In contrast to other reviews, we mentioned some commonly used medicines in CKD that may play a pivotal role in the pathogenesis of CI. Revealing the pathophysiology interactions between kidney damage and brain function can reduce the potential risk of future CI. This review will deeply explore the characteristics, indicators, and potential pathophysiological mechanisms of CKD-related CI. It will provide a theoretical basis for identifying CI that progresses during CKD and ultimately prevents and treats CKD-related CI.
Effects of short-term 17 beta-estradiol treatment on the properties of T4-binding proteins in the plasma of immature rainbow trout, Oncorhynchus mykiss.

D. Cyr,J. Eales

The Journal of Experimental Zoology

Abstract:To determine the effects of 17 beta-estradiol (E2) on the properties of the plasma proteins that bind L-thyroxine (T4) immature rainbow trout, Oncorhynchus mykiss, were injected intraperitoneally on days 0 and 3 with 0.5 mg E2-3-benzoate/100 g body weight, and plasma was sampled on days 4, 7, or 12. Control trout received peanut oil alone. E2 caused a small but significant decrease in the free T4 index. Saturation analysis on miniature G-25 Sephadex columns revealed at least two major T4-binding sites. Filtration on agarose Bio-gel A 1.5 also indicated two major T4-binding protein fractions with molecular weights of 150 and 55 kDa with a small proportion of T4 binding to a 1,500-kDa site presumed to be lipoprotein. Addition of unlabeled T4 displaced [125I]T4 from the 55-kDa site and unmasked an adjacent site of higher molecular weight. E2 increased the proportion of T4 bound to the low-affinity (150 kDa) site relative to that bound to the high-affinity (55 kDa) site, increased the level of protein associated with the 1,500-kDa site and its T4 binding, and also initiated the production of presumed vitellogenin (VTG), which bound a small amount of T4. It is concluded that the E2-induced depression in FT4 is caused by a shift in T4 binding between high-affinity and low-affinity sites, and also by binding of small amounts of T4 to presumed lipoprotein and VTG.
Elucidating the complex interplay between chronic kidney disease and hypertension

Daisuke Nagata,Erika Hishida

DOI: https://doi.org/10.1038/s41440-024-01937-8

2024-10-17

Hypertension Research

Abstract:Chronic kidney disease (CKD) and hypertension share a complex relationship, each exacerbating the progression of the other. CKD contributes to hypertension by decreasing renal function, leading to fluid retention and increased plasma volume, whereas hypertension exacerbates CKD by increasing glomerular pressure and causing renal damage. This review examines the intertwined nature of CKD and hypertension, exploring the factors driving hypertension in CKD and how hypertension accelerates CKD progression. It discusses the role of the renin-angiotensin system and inflammatory cytokines in this relationship, as well as the potential of blood pressure management to slow renal decline. While studies suggest that meticulous blood pressure control can help attenuate CKD progression, optimal management strategies remain unclear and require further investigation. This review also evaluates the evidence surrounding strict antihypertensive therapy in patients with CKD, considering both diabetic and non-diabetic cases. It recommends blood pressure targets based on CKD stage and presence of diabetes, emphasizing the importance of individualized treatment approaches. Renin-angiotensin system inhibitors are highlighted as a key pharmacological intervention due to their renal protective effects, particularly in patients with CKD with proteinuria. However, evidence regarding their efficacy in patients with CKD but without proteinuria is inconclusive. This review underscores the need for comprehensive approaches to effectively address the intertwined nature of CKD and hypertension and calls for further research to optimize clinical management strategies in this complex interplay.

peripheral vascular disease

Differences in the peritoneal response to pristane in BALB/cAnPt and BALB/cJ mice.

Stroke and Distal Organ Damage: Exploring Brain-Kidney Crosstalk

Kidney–brain crosstalk in the acute and chronic setting

Cerebrovascular Disease, Cardiovascular Disease, and Chronic Kidney Disease: Interplays and Influences

Mechanisms of Stroke in Patients with Chronic Kidney Disease

Stroke‐Induced Renal Dysfunction: Underlying Mechanisms and Challenges of the Brain–Kidney Axis

Navigating the Crossroads: Understanding the Link Between Chronic Kidney Disease and Cardiovascular Health

Epidemiology and Mechanisms of Uremia-Related Cardiovascular Disease.

A general four-parameter non-FSAL embedded Runge-Kutta algorithm of orders 6 and 4 in seven stages

The impact of chronic kidney disease on prognosis in acute stroke: unraveling the pathophysiology and clinical complexity for optimal management

Stroke in Dialysis and Chronic Kidney Disease

Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches

[Staphylococcal infection in a surgical clinic (review of foreign literature)].

Novel Perspectives in Chronic Kidney Disease-Specific Cardiovascular Disease

Neuropsychiatric Disorders in Chronic Kidney Disease

Performance of a hybrid-loop bioreactor system in biological treatment of 2,4,6-tri-chlorophenol containing synthetic wastewater: effects of hydraulic residence time.

The impact of chronic kidney disease on cognitive function

Technische und organisatorische Aspekte von Softwaretests (Technical and organizational aspects of testing software)

Kidney-brain axis in the pathogenesis of cognitive impairment

Effects of short-term 17 beta-estradiol treatment on the properties of T4-binding proteins in the plasma of immature rainbow trout, Oncorhynchus mykiss.

Elucidating the complex interplay between chronic kidney disease and hypertension